Literature DB >> 8367595

Oncogene- transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype.

K F Pirollo1, Y A Tong, Z Villegas, Y Chen, E H Chang.   

Abstract

Oncogenes and their normal counterparts, proto-oncogenes, are functionally important cellular genes which interact with one another as components of signal transduction pathways leading to cell growth and differentiation. Numerous reports in the literature have also begun to link these genes to the phenomenon of cellular radiation resistance. In this report we examine the radiation resistance level of NIH 3T3 cells transformed by various oncogenes in an attempt to define the intracellular pathway to the radiation-resistant phenotype. The results demonstrate that an analogous signaling pathway is apparently involved in acquisition of radiation resistance. Serine/threonine protein kinase oncogenes such as raf, mos, and PKC play a central role in the pathway. Moreover, specific oncogenes upstream (sis, HER-2, met, trk, and ras) and downstream (ets and myc) of these important signaling mediators can also influence the radiation resistance level of the cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8367595

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  9 in total

1.  PTK7 regulates radioresistance through nuclear factor-kappa B in esophageal squamous cell carcinoma.

Authors:  Misun Park; Hyeon-Joon Yoon; Moon Chul Kang; Junhye Kwon; Hae Won Lee
Journal:  Tumour Biol       Date:  2016-08-24

2.  Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.

Authors:  Maria J Sambade; J Terese Camp; Randall J Kimple; Carolyn I Sartor; Janiel M Shields
Journal:  Radiother Oncol       Date:  2009-10-23       Impact factor: 6.280

Review 3.  Breast cancer subtypes: response to radiotherapy and potential radiosensitisation.

Authors:  F E Langlands; K Horgan; D D Dodwell; L Smith
Journal:  Br J Radiol       Date:  2013-02-07       Impact factor: 3.039

4.  Expression of integrin-linked kinase is increased in differentiated cells.

Authors:  Michael Haase; Christine C Gmach; Iris Eke; Stephanie Hehlgans; Gustavo B Baretton; Nils Cordes
Journal:  J Histochem Cytochem       Date:  2008-05-27       Impact factor: 2.479

5.  The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution.

Authors:  Frédérique Mégnin-Chanet; François Lavelle; Vincent Favaudon
Journal:  BMC Pharmacol       Date:  2002-02-06

6.  Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity.

Authors:  H M Warenius; M Jones; T Gorman; R McLeish; L Seabra; R Barraclough; P Rudland
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

7.  Inhibition of I kappaB-alpha phosphorylation at serine and tyrosine acts independently on sensitization to DNA damaging agents in human glioma cells.

Authors:  J Miyakoshi; K Yagi
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

8.  Association of Human Epidermal Growth Factor Receptor 2 with Radiotherapy Resistance in Patients with T1N0M0 Breast Cancer.

Authors:  Hyun-Ah Kim; Eun-Kyu Kim; Min-Soo Kim; Jong-Han Yu; Mi-Ri Lee; Hae Kyung Lee; Young-Jin Suh; Woo Chul Noh
Journal:  J Breast Cancer       Date:  2013-09-30       Impact factor: 3.588

9.  Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.

Authors:  Yu-Li Su; Shan-Hsuan Li; Yen-Yang Chen; Hui-Chun Chen; Yen Tang; Cheng-Hua Huang; Fong-Fu Chou; Shih-Chung Wu; Kun-Ming Rau
Journal:  Radiol Oncol       Date:  2014-07-10       Impact factor: 2.991

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.